Login or sign up
For business

Oncomatryx biopharma

4.1· 10 reviews
Average ratingGreat
4.1/ 5

Based on 10 reviews

540%
430%
330%
20%
10%
Ask AI

Ask AI about Oncomatryx biopharma

Generated with AI from 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Alonso Arellano
Reviews 1

The experience I had with this biopharma company was truly outstanding. The website was easy to navigate and provided a wealth of information about their innovative products and technologies. I was particularly impressed with the comprehensive portfolio of oncology therapies they offer, which clearly demonstrates their dedication to advancing cancer treatment. The website also showcased their collaborative approach with leading academic institutions and pharmaceutical companies, further emphasizing their commitment to excellence. The company's commitment to promoting sustainable practices and their focus on the development of novel drug delivery systems are also highly commendable. Overall, I found their website to be a valuable resource for anyone seeking cutting-edge solutions in the field of oncology. I would highly recommend this company to anyone looking for an excellent partner in the fight against cancer.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Oncomatryx biopharma

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.

Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.

Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression.

Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

Categories
Pharmaceuticals